ArticleBiosensors & bioelectronics2011
Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array.
Article in Biosensors & bioelectronics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.Biomolecules · 2025Review
- Ultrathin Covalent Organic Framework Nanosheets/TiMolecules (Basel, Switzerland) · 2022Article
- Comparing digital detection platforms in high sensitivity immune-phenotyping of extracellular vesicles.Journal of extracellular biology · 2022Article
- Use of data processing for rapid detection of the prostate-specific antigen biomarker using immunomagnetic sandwich-type sensors.Beilstein journal of nanotechnology · 2019Article
- Height Resolution of Antibody Spots Measured by Spinning-Disk Interferometry on the BioCD.Micromachines · 2016Article
- Interferometric methods for label-free molecular interaction studies.Analytical chemistry · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fluorescence-free biosensor arrays for protein detection directly measure the protein surface density, and do not require a fluorophore or enzyme label, and provide quantitative and consistent signals. However, few fluorescence-free biosensor protein arrays have demonstrated successful application in high-background samples, such as serum, due to non-specific binding. We tested the BioCD as a fluorescence-free biosensor based on optical interferometry, and used it to detect prostate specific antigen (PSA, a biomarker of prostate cancer) in patient sera in a 96-well anti-PSA microarray. We have attained a 4 ng/ml detection limit in serum and have measured PSA concentrations in patient sera. The measured concentrations correlated well with enzyme-linked immunosorbent assay (ELISA) results. The measurement of PSA concentrations in high-level protein backgrounds suggests that the BioCD has a potential for clinical applications by removing the restriction of fluorescence-free biosensors from high-background applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.